Cited by 368Bone Metabolism and DiseasesRheumatoid Arthritis Research and TherapiesNatural Compounds in Disease Treatment

Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis

Open access
Romas, Evan, Sims, Natalie A., Hards, Daphne K., Lindsay, Mandy, Quinn, Julian W.M., Ryan, Peter F.J., Dunstan, Colin R., Martin, T. John +1 more·2002·The American Journal of Pathology

Abstract

Rheumatoid arthritis is characterized by progressive synovial inflammation and joint destruction. While matrix metalloproteinases (MMPs) are implicated in the erosion of unmineralized cartilage, bone destruction involves osteoclasts, the specialized cells that resorb calcified bone matrix. RANK ligand (RANKL) expressed by stromal cells and T cells, and its cognate receptor, RANK, were identified as a critical ligand-receptor pair for osteoclast differentiation and survival. A decoy receptor for RANKL, osteoprotegerin, (OPG) impinges on this system and regulates osteoclast numbers and activity. RANKL is also expressed in collagen-induced arthritis (CIA) in which focal collections of osteoclasts are prominent at sites of bone destruction. To determine the role of RANK signaling events in the effector phase of CIA, we investigated effects of Fc-osteoprotegerin fusion protein (Fc-OPG) in CIA. After induction of CIA in Dark Agouti rats, test animals were treated with or without Fc-OPG (3 mg/kg/day) subcutaneously for 5 days, beginning at the onset of disease. Paraffin-embedded joints were then analyzed histologically and the adjacent bone assessed by histomorphometry. Osteoclasts were identified using TRAP staining and expression of the mRNA for OPG and RANKL was identified by in situ hybridization. The results indicated that short-term Fc-OPG effectively prevented joint destruction, even though it had no impact on the inflammatory aspects of CIA. In arthritic joints, Fc-OPG depleted osteoclast numbers by over 75% and diminished bone erosion scores by over 60%. Although cartilage loss was also reduced by Fc-OPG, the effects on cartilage were less striking than those on bone. In arthritic joints OPG mRNA was highly expressed and co-localized with RANK ligand, and treatment with Fc-OPG did not affect the expression of endogenous RANKL or OPG mRNA. These data demonstrate that short term Fc-OPG treatment has powerful anti-erosive effects, principally on bone, even though synovitis is not affected. These findings indicate the potential utility of disrupting RANK signaling to preserve skeletal integrity in inflammatory arthritis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)64417-3

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PFJ, Martin TJ, Gillespie MT: Expression of osteoclast differen- tiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000, 43:821-826
  2. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250 -258
  3. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Taka- hashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Taka- hashi N, Togari A, Tomatsu T, Suda T, Kamatani N: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012
  4. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factorB/osteoclast differentiation factor in oste- oclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259 -269
  5. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D: Efficacy of sustained levels of interleukin-1 receptor antagonist in animal models of arthritis. Arthritits Rheum 1999, 43:498 -506
  6. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT: Localization of RANKL mRNA and protein in skeletal and extra-skeletal tissues. Bone 1999, 25:525-534

Cited by

Sorted by citations

Authors
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T.
Affiliations
  • The University of Melbourne (AU)
  • St Vincents Institute of Medical Research (AU)
  • Monash University (AU)
  • Amgen (United States) (US)
Corresponding author
Romas, Evan
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2002-10
Volume
161
Issue
4
Pages
1419-1427
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2032384549
Cited by
368
References
44
Citations by year
2026: 1 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 8 · 2018: 7 · 2017: 1 · 2016: 5 · 2015: 17 · 2014: 12 · 2013: 3 · 2012: 16
FWCI
19.64
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Arthritis Foundation
  • Arthritis Foundation of Australia
  • National Health and Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
osteoprotegerin, collagen-induced arthritis, rheumatoid arthritis, osteoclasts, bone erosion, RANK ligand, RANK signaling, joint destruction, cartilage destruction, synovitis
MeSH terms
Animals, Arthritis, Experimental, Bone Diseases, Carrier Proteins, Collagen, Glycoproteins, Membrane Glycoproteins, Osteoclasts, Time Factors, Transcription, Genetic, Tumor Necrosis Factor-alpha, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Rats, Osteoprotegerin, RANK Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review